Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Camille McGaw

Gastroenterology St Augustine, FL Medical Doctor

NPI 1154640779 CMS profile 1307621

40 Groover Loop Ste 200, St Augustine, FL 32086

Open in the dashboard

General payments

$7,416

423 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Camille McGaw of St Augustine, FL is reported in the CMS Open Payments database as having received $7,416 across 423 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,169 106
2024 General $1,652 95
2023 General $1,556 93
2022 General $853 50
2021 General $668 43
2020 General $168 10
2019 General $351 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Camille McGaw
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Camille McGaw were reported at $2,169. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Camille McGaw Gastroenterology median Middle half National median
2019 $351 $417 $126–$1,100 $163
2020 $168 $224 $74–$624 $114
2021 $668 $352 $106–$1,054 $132
2022 $853 $448 $129–$1,270 $149
2023 $1,556 $533 $150–$1,390 $160
2024 $1,652 $605 $160–$1,606 $164
2025 $2,169 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,969 124 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $830 47 payments
  3. Janssen Biotech, Inc. $653 38 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $538 34 payments
  5. Madrigal Pharmaceuticals $453 15 payments
  6. Lilly USA, LLC $320 22 payments
  7. Regeneron Healthcare Solutions, Inc. $291 14 payments
  8. Merck Sharp & Dohme Corporation $265 17 payments
  9. Genzyme Corporation $235 11 payments
  10. Pfizer Inc. $230 15 payments
  11. Other $1,634 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,290 421 payments
  2. Education $126 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $702 36 payments
  2. ENTYVIO $546 28 payments
  3. SKYRIZI $499 26 payments
  4. LINZESS $487 38 payments
  5. REZDIFFRA $405 12 payments
  6. STELARA $401 22 payments
  7. CREON $388 32 payments
  8. XIFAXAN $387 25 payments
  9. HUMIRA $333 22 payments
  10. OMVOH $320 22 payments
  11. Other $4,131 241 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,213

Median for Gastroenterology: 569

Drug cost

$146,683

Median for Gastroenterology: $104,976

Branded share of claims

28.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 89 $84,075
Zenpep Lipase/Protease/Amylase Brand 12 $20,952
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 169 $10,289
Mesalamine Generic 18 $7,194
Mesalamine Er Mesalamine Brand 14 $4,850
Pantoprazole Sodium Generic 413 $4,359
Omeprazole Generic 254 $3,974
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 20 $3,250
Azathioprine Generic 20 $3,176
Cholestyramine Cholestyramine (With Sugar) Brand 20 $1,097

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$126,506

Medicare's payments for the services billed

Medicare patients

500

Average age 73

Services billed

3,139

339 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 59%
Ischemic heart disease 38%
Chronic kidney disease 28%
Depression 28%
Diabetes 27%
Atrial fibrillation 24%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $237
$237 — —
RINVOQ
  • AbbVie, Inc. $148
$148 — —
OMVOH
  • Lilly USA, LLC $147
$147 — —
DUPIXENT
  • GENZYME CORPORATION $72
  • Regeneron Healthcare Solutions, Inc. $36
$108 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record